GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stealth BioTherapeutics Corp (NAS:MITO) » Definitions » Gross Profit

Stealth BioTherapeutics (Stealth BioTherapeutics) Gross Profit : $0.00 Mil (TTM As of Mar. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Stealth BioTherapeutics Gross Profit?

Stealth BioTherapeutics's gross profit for the three months ended in Mar. 2022 was $0.00 Mil. Stealth BioTherapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Stealth BioTherapeutics's gross profit for the three months ended in Mar. 2022 was $0.00 Mil. Stealth BioTherapeutics's Revenue for the three months ended in Mar. 2022 was $0.00 Mil. Therefore, Stealth BioTherapeutics's Gross Margin % for the quarter that ended in Mar. 2022 was N/A%.

Stealth BioTherapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2022 => No sustainable competitive advantage


Stealth BioTherapeutics Gross Profit Historical Data

The historical data trend for Stealth BioTherapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stealth BioTherapeutics Gross Profit Chart

Stealth BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Profit
Get a 7-Day Free Trial - - 21.09 - -

Stealth BioTherapeutics Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stealth BioTherapeutics's Gross Profit

For the Biotechnology subindustry, Stealth BioTherapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stealth BioTherapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stealth BioTherapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Stealth BioTherapeutics's Gross Profit falls into.



Stealth BioTherapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Stealth BioTherapeutics's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Stealth BioTherapeutics's Gross Profit for the quarter that ended in Mar. 2022 is calculated as

Gross Profit (Q: Mar. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Stealth BioTherapeutics's Gross Margin % for the quarter that ended in Mar. 2022 is calculated as

Gross Margin % (Q: Mar. 2022 )=Gross Profit (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Stealth BioTherapeutics  (NAS:MITO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Stealth BioTherapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2022 => No sustainable competitive advantage


Stealth BioTherapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Stealth BioTherapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Stealth BioTherapeutics (Stealth BioTherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Intertrust Corporate Services (Cayman) Limited, One Nexus way, Camana Bay, Grand Cayman, CYM, KY1-9005
Stealth BioTherapeutics Corp is a clinical-stage biotechnology company. It is focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

Stealth BioTherapeutics (Stealth BioTherapeutics) Headlines

From GuruFocus

Stealth BioTherapeutics Corp Announces Completion of Merger

By PRNewswire PRNewswire 11-16-2022